Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 41 to 50 of 2245 total matches.
Elbasvir/Grazoprevir (Zepatier) for Hepatitis C
The Medical Letter on Drugs and Therapeutics • Feb 29, 2016 (Issue 1489)
of chronic hepatitis C virus (HCV) genotype 1 or 4
infection.
Pronunciation Key
Elbasvir : elb' as veer ...
The FDA has approved Zepatier (Merck), a fixed-dose
combination of two direct-acting antiviral
agents — elbasvir, an NS5A inhibitor, and grazoprevir,
an NS3/4A protease inhibitor — for oral treatment
of chronic hepatitis C virus (HCV) genotype 1 or 4
infection.
Azelastine/Fluticasone Propionate (Dymista) for Seasonal Allergic Rhinitis
The Medical Letter on Drugs and Therapeutics • Oct 29, 2012 (Issue 1402)
-antihistamine, such as loratadine
(Claritin, and generics) or fexofenadine (Allegra, and
generics).1 ...
The FDA has approved a nasal spray fixed-dose combination (Dymista – Meda) of the H1-antihistamine azelastine (Astelin, Astepro, and generics) and the corticosteroid fluticasone propionate (Flonase, and generics) for treatment of seasonal allergic rhinitis (SAR) in patients ≥12 years old who need both medications for symptomatic relief. It is the first nasal spray to be approved in the US that contains both an H1-antihistamine and a corticosteroid.
Pembrolizumab (Keytruda) for First-Line Treatment of Metastatic NSCLC
The Medical Letter on Drugs and Therapeutics • Jan 30, 2017 (Issue 1513)
the immune checkpoint inhibitor
pembrolizumab (Keytruda – Merck), a programmed
death receptor-1 (PD-1 ...
The FDA has approved the immune checkpoint inhibitor
pembrolizumab (Keytruda – Merck), a programmed
death receptor-1 (PD-1) inhibitor, for first-line treatment
of patients with metastatic non-small cell lung cancer
(NSCLC) that highly expresses programmed death-ligand
1 (PD-L1) and has no epidermal growth factor
receptor (EGFR) mutations or anaplastic lymphoma
kinase (ALK) translocations. About 25% of patients with
advanced NSCLC have tumors with high levels of PD-L1
expression (PD-L1 expressed on ≥50% of tumor cells).
Pembrolizumab was approved earlier for treatment...
Semaglutide (Wegovy) for Weight Loss
The Medical Letter on Drugs and Therapeutics • Jul 12, 2021 (Issue 1628)
of obesityrelated
comorbidities.4
MECHANISM OF ACTION — Activation of brain GLP-1
receptors potentiates glucose ...
The injectable glucagon-like peptide-1 (GLP-1)
receptor agonist semaglutide, previously approved
by the FDA as Ozempic to treat type 2 diabetes and
to reduce the risk of major adverse cardiovascular
events in adults with type 2 diabetes and established
cardiovascular disease, has now been approved in
a higher dose as Wegovy (Novo Nordisk) for chronic
weight management in adults with or without type 2
diabetes who have a body mass index (BMI) ≥30 kg/m2
or a BMI ≥27 kg/m2 and ≥1 weight-related comorbidity
(e.g., hypertension, dyslipidemia). An oral formulation
of semaglutide...
Alpha1-Proteinase Inhibitor for Alpha1-Antitrypsin Deficiency
The Medical Letter on Drugs and Therapeutics • Mar 11, 1988 (Issue 761)
FOR
ONLINE USERS
ALPHA
1
-PROTEINASE INHIBITOR FOR
ALPHA
1
-ANTITRYPSIN DEFICIENCY
Human alpha
1 ...
Human alpha1-proteinase inhibitor (Prolastin Cutter), possibly better known as alpha1-antitypsin (ATT), is now available in the USA for replacement therapy in patients with emphysema who have a congential deficiency of the protein.
Plenvu - A Low-Volume PEG-Based Colonoscopy Preparation
The Medical Letter on Drugs and Therapeutics • Jan 28, 2019 (Issue 1564)
in adults.
Plenvu is the first PEG-containing colonoscopy preparation
that requires only 1 L of water ...
The FDA has approved Plenvu (Salix), a polyethylene
glycol (PEG)-containing oral powder for reconstitution,
for colon cleansing prior to colonoscopy in adults.
Plenvu is the first PEG-containing colonoscopy preparation
that requires only 1 L of water for dissolution and
ingestion of 1 L of clear fluid in addition.
Tretinoin/Benzoyl Peroxide Cream (Twyneo) for Acne
The Medical Letter on Drugs and Therapeutics • May 16, 2022 (Issue 1650)
trials included applicationsite
pain (10.6%), dryness (4.9%), exfoliation (4.1%),
erythema (4.0 ...
The FDA has approved Twyneo (Galderma), a cream
containing the retinoid tretinoin and the oxidizing
agent benzoyl peroxide, for once-daily topical
treatment of acne in patients ≥9 years old.
Cefiderocol (Fetroja) - A New IV Cephalosporin for Complicated UTI
The Medical Letter on Drugs and Therapeutics • May 04, 2020 (Issue 1597)
a cephalosporin or a carbapenem with
a beta-lactamase inhibitor such as ceftazidime/
avibactam (Avycaz),1 ...
The FDA has approved cefiderocol (Fetroja – Shionogi),
a new IV cephalosporin antibiotic, for treatment of
complicated urinary tract infections (UTI) caused by
susceptible gram-negative bacteria in adults who
have limited or no alternative treatment options.
Antibacterial Prophylaxis for Dental, GI and GU Procedures
The Medical Letter on Drugs and Therapeutics • Jul 18, 2005 (Issue 1213)
practice has
never been established by controlled trials in humans.
1
The drugs and dosages in the table ...
Many physicians believe that antimicrobial prophylaxis before procedures that may cause transient bacteremia can prevent endocarditis and prosthetic joint infection in patients at increased risk for these disorders. The effectiveness of this common practice has never been established by controlled trials in humans.
Trifarotene (Aklief) - A New Topical Retinoid for Acne
The Medical Letter on Drugs and Therapeutics • Dec 16, 2019 (Issue 1587)
by
prescription for decades. Adapalene 0.1% gel has been
available over the counter since 2016 for treatment ...
The FDA has approved trifarotene 0.005% cream
(Aklief – Galderma) for topical treatment of acne
vulgaris in patients ≥9 years old. Trifarotene is the
fourth topical retinoid to be approved in the US for
treatment of acne; tretinoin (Retin-A, and others),
adapalene (Differin, and generics), and tazarotene
(Tazorac, and others) have been available by
prescription for decades. Adapalene 0.1% gel has been
available over the counter since 2016 for treatment of
acne in patients ≥12 years old.